Phase 2 Clinical Studies for Degludec Insulin Completed
Degludec is a type of insulin made by Novo Nordisk. It is an ultra-long lasting insulin. It is said to be as effective as Lantus with less does per day. During the clinical trials, diabetics took degludec three times a week and maintained excellent control over their diabetes.
Clinical Study Phase 2
“A randomized, double-blind, parallel-group, euglycaemic glucose clamp study1 in 54 patients with type 1 diabetes demonstrated that, under steady-state conditions after once-daily administration, the effect of insulin degludec is evenly distributed over each 24 hour period. The metabolic effect of insulin degludec was evenly distributed between the first and the second 12 hours and this distribution was also less variable than with insulin glargine.”
With phase 2 clinical studies, completed and successful Novo Nordisk will begin phase 3 clinical studies in the near future.